Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus.

PubWeight™: 2.40‹?› | Rank: Top 2%

🔗 View Article (PMC 2139691)

Published in J Exp Med on June 01, 1974

Authors

H Kirchner, T M Chused, R B Herberman, H T Holden, D H Lavrin

Articles citing this

Suppressor thymus-derived lymphocytes in fungal infection. J Clin Invest (1976) 3.65

Soluble suppressor factors in patients with acquired immune deficiency syndrome and its prodrome. Elaboration in vitro by T lymphocyte-adherent cell interactions. J Clin Invest (1983) 1.72

Concanavalin A-activated suppressor cells in normal human peripheral blood lymphocytes. Clin Exp Immunol (1976) 1.61

Characterization of cytotoxic spleen cells and effects of serum factors in a syngeneic rat tumour system. Br J Cancer (1976) 1.53

Influence of dietary restriction on immunologic function and renal disease in (NZB x NZW) F1 mice. Proc Natl Acad Sci U S A (1978) 1.52

Lymphocyte reactivity to mitogens in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Clin Exp Immunol (1977) 1.39

Influence of malaria infection on the elaboration of soluble mediators by adherent mononuclear cells. Infect Immun (1979) 1.27

Mechanisms of genetic resistance to Friend virus leukemia. III. Susceptibility of mitogen-responsive lymphocytes mediated by T cells. J Exp Med (1976) 1.27

Inhibition of polyclonal B-cell activation by suppressor monocytes in patients with sarcoidosis. Clin Exp Immunol (1978) 1.25

Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y. Proc Natl Acad Sci U S A (1977) 1.22

The potentiating, mitogenic and inhibitory effects on lymphocytes in vitro, of macrophages in the lymph nodes of mice 'overloaded' with mycobacterial products. Clin Exp Immunol (1975) 1.21

Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. J Clin Invest (1991) 1.07

T lymphocyte function as the principal target of lymphocytic choriomeningitis virus-induced immunosuppression. Infect Immun (1975) 1.06

Evaluation of Mycobacterium leprae immunogenicity via adoptive transfer studies. Infect Immun (1984) 1.01

Studies on the pathogenesis of an immune defect in multiple myeloma. J Clin Invest (1977) 1.01

Radiation-induced augmentation of the response of A/J mice to SaI tumor cells. Am J Pathol (1982) 0.98

Immunity to murine sarcoma virus induced tumours. IV. Direct cellular cytolysis of 51Cr labelled target cells in vitro and analysis of blocking factors which modulate cytotoxicity. Br J Cancer (1975) 0.95

Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients. Br J Cancer (1978) 0.95

Non-specific inhibition by virus particles of human lymphocytes mitogenesis. Clin Exp Immunol (1980) 0.93

Characterization of a T-lymphocyte inhibitor in the serum of tumour-bearing mice. Immunology (1976) 0.89

The effects of T-cell growth factor and virus purification on virus-mediated inhibition of lymphocyte mitogenesis. Clin Exp Immunol (1982) 0.87

Suppression and enhancement of mitogen response in chickens infected with Marek's disease virus and the herpesvirus of turkeys. Infect Immun (1978) 0.86

Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85

Evidence for suppressor cell activity associated with induction of Herpesvirus saimiri-induced lymphoma. Clin Exp Immunol (1975) 0.85

Surface markers of small lymphocytes appearing in the mouse Ehrlich ascites tumour, host spleen and blood. Immunology (1978) 0.85

Naturally occurring lymphocyte-mediated immunity to endogenous type-C virus in the mouse. Blocking of the lymphocyte reactivity with antisera to the virus. J Exp Med (1979) 0.85

In vitro generation of cytotoxic lymphocytes against radiation- and radiation leukemia virus-induced tumors. III. Suppression of anti-tumor immunity in vitro by lymphocytes of mice undergoing radiation leukemia virus-induced leukemogenesis. J Exp Med (1980) 0.81

Differential sensitivity of CD8+ suppressor and cytotoxic T lymphocyte activity to bacterial monophosphoryl lipid A. Infect Immun (1991) 0.81

Suppressive effect of secondary Toxoplasma gondii infection on antibody responses in mice. Infect Immun (1985) 0.79

Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T-cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells. Immunology (1981) 0.79

T-T hybridoma product specifically suppresses tumor immunity. Proc Natl Acad Sci U S A (1980) 0.79

Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs. BMC Vet Res (2012) 0.78

Recovery of immune competence after tumour resection in mice: correlation with loss of suppressor elements. Br J Cancer (1978) 0.78

Regulation of the immune response to bacterial lipopolysaccharide by adherent cells. Infect Immun (1981) 0.77

Induction of suppressor macrophages in mice by Fusarenon-X. Immunology (1982) 0.77

Tumour-induced suppressor macrophages in rats: differences in their suppressive effects on the Con A and PHA responses. Clin Exp Immunol (1984) 0.76

Resurgence of killing and in vivo protection mediated by lymphocytes cultured from lymph nodes draining Moloney sarcomas. Br J Cancer (1978) 0.75

Correlation of suppressor cell development in parental and F1 hybrid mouse strains with the growth of a parental tumor in vivo. J Exp Med (1976) 0.75

Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice. Am J Pathol (1976) 0.75

Specificity in the immunosuppression induced by avian reticuloendotheliosis virus. Infect Immun (1983) 0.75

Enhancing and inhibiting effects of spleen cells from tumour-bearing mice on growth of virus-induced primary sarcoma. Br J Cancer (1978) 0.75

Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes. Br J Cancer (1976) 0.75

Articles cited by this

Immunization of dissociated spleen cell cultures from normal mice. J Exp Med (1967) 30.93

Further improvements in the plaque technique for detecting single antibody-forming cells. Immunology (1968) 24.83

THE AKR THYMIC ANTIGEN AND ITS DISTRIBUTION IN LEUKEMIAS AND NERVOUS TISSUES. J Exp Med (1964) 13.72

Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity. Lancet (1971) 7.98

Lymphocyte activation. I. Response of T and B lymphocytes to phytomitogens. Clin Exp Immunol (1971) 6.43

Selective induction of DNA synthesis in T and B lymphocytes. Cell Immunol (1972) 4.94

Evidence for the existence of two functionally distinct types of cells which regulate the antibody response to type 3 pneumococcal polysaccharide. J Immunol (1970) 3.94

Suppressor T cells. J Immunol (1972) 3.92

Impaired in vitro lymphocyte transformation in Hodgkin's disease. N Engl J Med (1965) 3.54

Biological effects of the adjuvant Corynebacterium parvum. I. Inhibition of PHA, mixed lymphocyte and GVH reactivity. Cell Immunol (1972) 2.57

Regulation of lymphocyte responses in vitro. 3. Inhibition by adherent cells of the T-lymphocyte response to phytohemagglutinin. J Immunol (1973) 1.92

Inhibition of spleen cell DNA synthesis by autologous macrophages. J Immunol (1966) 1.84

Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J (1957) 1.74

Amplifying and suppressive effect of thymus cells. Nature (1971) 1.65

In vitro transformation of mouse bone-marrow-derived (B) lymphocytes induced by the lipid component of endotoxin. Infect Immun (1973) 1.62

Cell-mediated immune reaction against tumors induced by oncornaviruses. II. Nature of the effector cells in tumor-cell cytolysis. Int J Cancer (1973) 1.49

Specificity of antigen recognition by human lymphocytes in vitro. Science (1970) 1.48

Effect of antibody to theta antigen on cell-mediated immunity induced in syngeneic mice by murine sarcoma virus. J Natl Cancer Inst (1973) 1.45

Enhanced antibody response of mice to polyinosinic-polycytidylic acid by antithymocyte serum and its age-dependent loss in NZB-W mice. J Immunol (1973) 1.40

Experimental studies in tumor imminology. Fed Proc (1970) 1.28

Effect of allogeneic cell interaction on the primary immune response in vitro. Cell types involved in suppression and stimulation of antibody synthesis. Clin Exp Immunol (1972) 1.27

Comparative studies on the induction of transplantation resistance in BALB-c and C57BL-6 mice in three murine leukemia systems. Cancer Res (1967) 1.22

Lymphocyte response to P.H.A. in patients with non-lymphoid tumours. Lancet (1970) 1.18

Inhibition of phytohemagglutinin-induced in vitro lymphocyte transformation by serum from patients with carcinoma. J Natl Cancer Inst (1971) 1.17

Possibilities and problems of immunologic intervention in cancer. N Engl J Med (1972) 1.14

In vitro cooperation of cells of bone marrow and thymus origins in the generation of antibody-forming cells. J Immunol (1972) 1.14

Inhibition of phytohemagglutinin- and alloantigen-induced lymphocyte stimulation by Rauscher leukemia virus. J Natl Cancer Inst (1970) 1.04

Separation of human lymphoid cells into G 1 , S, and G 2 cell cycle populations by use of a velocity sedimentation technique. J Exp Med (1973) 1.03

In vitro cytotoxicity studies of murine sarcoma virus-induced immunity in mice. J Natl Cancer Inst (1973) 1.00

Thymic dependency of tumor-induced immunodepression. J Natl Cancer Inst (1973) 0.94

Immune capacity and response to antigenic tumors. Cancer Res (1973) 0.81

Articles by these authors

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 5.91

Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med (1981) 5.76

Natural cell-mediated immunity. Adv Cancer Res (1978) 5.53

Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63

Natural killer cells: their roles in defenses against disease. Science (1981) 4.59

Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer (1975) 3.54

Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J Immunol (1977) 3.52

Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26

Antiviral effects of recombinant tumour necrosis factor in vitro. Nature (1986) 3.25

Natural killer cells: characteristics and regulation of activity. Immunol Rev (1979) 3.14

Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol (1984) 3.07

Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol (1981) 3.05

The immunobiology of zinc. Immunol Today (1997) 2.93

Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest (1984) 2.88

Early T lymphocytes. Differentiation in vivo of adult intrathymic precursor cells. J Exp Med (1985) 2.81

Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol (1979) 2.80

Ferrous-activated nicotinamide adenine dinucleotide-linked dehydrogenase from a mutant of Escherichia coli capable of growth on 1, 2-propanediol. J Bacteriol (1969) 2.66

A functional comparison of human Fc-receptor-bearing lymphocytes active in natural cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol (1977) 2.60

Heterogeneity of natural killer cells. Annu Rev Immunol (1984) 2.59

Molecular events in the induction of a nonresponsive state in interleukin 2-producing helper T-lymphocyte clones. Proc Natl Acad Sci U S A (1987) 2.57

High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis (1998) 2.48

Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46

Loss with age in NZB-W mice of thymic suppressor cells in the graft-vs-host reaction. J Immunol (1974) 2.45

Expression of Lyt-1 by a subset of B lymphocytes. J Immunol (1982) 2.41

Augmentation of natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic target cells. Int J Cancer (1977) 2.39

Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med (1989) 2.33

Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum. J Immunol (1975) 2.13

Natural killer (NK) cell activity in the rat. I. Isolation and characterization of the effector cells. J Immunol (1981) 2.12

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (2004) 2.07

Demonstration of activation of B lymphocytes in New Zealand black mice at birth by an immunoradiometric assay for murine IgM. J Immunol (1977) 2.06

Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol (1983) 2.06

Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes. J Immunol (1986) 2.05

Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04

Low density of Thy 1 antigen on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol (1978) 2.04

XenCSA: cell surface antigens related to the major glycoproteins (gp70) of xenotropic murine leukemia viruses. J Immunol (1979) 2.02

Immunosuppressive activity of a subline of the mouse EL-4 lymphoma. Evidence for minute virus of mice causing the inhibition. J Exp Med (1976) 2.01

Genetic differences between primary and secondary sicca syndrome. N Engl J Med (1979) 1.93

Depletion of monocytes from human peripheral blood mononuclear leukocytes: comparison of the sephadex G-10 column method with other commonly used techniques. J Immunol Methods (1980) 1.92

Cytotoxic reactivity of human lymphocytes cultured in vitro. J Immunol (1977) 1.88

Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res (1989) 1.84

Cytolytic and cytostatic activity on tumor cells of circulating human monocytes. Int J Cancer (1979) 1.84

T-cell homeostasis in HIV infection is neither failing nor blind: modified cell counts reflect an adaptive response of the host. Nat Med (1997) 1.82

Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses. J Exp Med (1982) 1.81

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80

Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis. Am J Med (1979) 1.79

Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79

Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol (1983) 1.79

Chédiak-Higashi gene in humans I. Impairment of natural-killer function. J Exp Med (1980) 1.79

The clearance and localization of nucleic acids by New Zealand and normal mice. Clin Exp Immunol (1972) 1.74

Mechanism of cytotoxicity by natural killer (NK) cells. Annu Rev Immunol (1986) 1.72

Breast conservation versus mastectomy: distress sequelae as a function of choice. J Clin Oncol (1989) 1.70

Inhibition of murine natural killer cell activity by prostaglandins. J Immunol (1980) 1.68

Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. Transfus Med (2000) 1.67

Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66

Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62

Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction. Transfusion (1992) 1.60

Cell-mediated immunity to tumor cells. Adv Cancer Res (1974) 1.60

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58

Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand (1988) 1.57

Mastectomy versus breast conservation surgery: mental health effects at long-term follow-up. Health Psychol (1992) 1.56

Interferon treatment inhibits onset of herpes simplex virus immediate-early transcription. Virology (1988) 1.55

Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol (1996) 1.55

Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol (1985) 1.55

Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer (1972) 1.55

Fc receptors on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol (1977) 1.53

Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol (1976) 1.53

Natural killer (NK) cells and their possible roles in resistance against disease. Clin Immunol Rev (1981) 1.52

Lymphocyte membrane potential and Ca2+-sensitive potassium channels described by oxonol dye fluorescence measurements. J Cell Physiol (1985) 1.52

Cell-mediated cytotoxicity for bladder carcinoma: evaluation of a workshop. Cancer Res (1975) 1.51

Natural killer activity in the rat. II. Analysis of surface antigens on LGL by flow cytometry. J Immunol (1981) 1.51

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50

Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int J Cancer (1982) 1.50

Role of macrophages in the augementation of mouse natural killer cell activity by poly I:C and interferon. J Immunol (1979) 1.49

Identification and separation of Thy-1 positive mouse spleen cells active in natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Immunol (1979) 1.48

Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol (1999) 1.48

Differential expression of two distinct xenotropic viruses in NZB mice. Clin Immunol Immunopathol (1980) 1.48

Altered cytokine production in the elderly. Mech Ageing Dev (1998) 1.47

Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol (1979) 1.46

Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Correlation with clinical features. Am J Med (1982) 1.46

Demonstration of circulating immune complexes in Sjögren's syndrome. J Immunol (1979) 1.46

Production of immune interferon by murine T-cell clones from long-term cultures. Nature (1981) 1.45